Pasar al contenido principal

IDENTIFICACION Y CARACTERIZACION DE ESTRATEGIAS PARA MODULAR LA ACTIVIDAD DE LOS FIBROBLASTOS ASOCIADOS A CANCER PARA ENTORPECER EL DESARROLLO TUMORAL

RTI2018-096778-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Analysis of the role of the histone-deacetylases (HDACs) in the generation of cancer-associated fibroblasts (CAFs)

  • Subijana, María
  • Rodríguez, Javier
  • Calvo, Fernando
Trabajo presentado en el 18th ASEICA International Congress, celebrado en Santiago de Compostela (España) del 16 al 18 de noviembre de 2022., Cancer-associated fibroblasts (CAFs) are the major population within the tumour microenvironment (TME) in many solid carcinomas and generally present tumour-promoting functions, such as promotion of cancer cell growth, survival and invasion, angiogenesis and immunosuppression. Therefore, CAFs can critically regulate tumour initiation, progression and therapeutic response. § CAFs show a pathologically activated phenotype despite the absence of genomic aberrations, suggesting that epigenetic rearrangements might be involved in the emergence of pro-tumorigenic CAFs. § Our aim is to assess whether a dysregulation of the acetylation machinery, in particular of the histone-deacetylases (HDACs), leads to epigenetic rearrangements contributing to distinct CAF phenotypes. § Understanding how HDAC activity is regulated in fibroblasts and its overall effect on CAF emergence may inform of strategies to block the capacity of CAFs to shape aggressive environments. HDAC inhibitors, widely used in cancer therapy, could rise up as a novel approach for targeting tumour stroma., Grant PRE2019-088067 funded by MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”. Grant PID2021-128107OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. FC lab is funded by AECC (LABAE19044CALV), MCIN/AEI/ 10.13039/501100011033 (RTI2018-096778-A-I00, PID2021-128107OB-I00); AECC (PRYCO211372RODR); BBVA Leonardo Awards (IN[19]_BBM_BAS_0076), and the ERC (ERC-CoG101045756).